Benign Bone Lesion With Incidental 18 F-PR04.MZ Uptake on PET/CT in a Patient With Parkinson's Disease

Area of Science:

• Nuclear Medicine
• Neurology
• Radiology

Background:

• Parkinson's disease is characterized by reduced dopamine transporter (DAT) levels in the striatum.
• Positron Emission Tomography/Computed Tomography (PET/CT) is used to visualize DAT.
• Novel radiopharmaceuticals are being developed for improved diagnostic accuracy.

Purpose of the Study:

• To evaluate the utility of the novel radiopharmaceutical 18F-PR04.MZ for dopamine transporter (DAT) imaging in a patient with Parkinson's disease.
• To report an incidental finding during DAT PET/CT imaging.

Main Methods:

• PET/CT imaging was performed using the novel radiotracer 18F-PR04.MZ.
• Standard analysis of striatal uptake was conducted.
• Computed Tomography (CT) was used to characterize unexpected focal radiotracer accumulation.

Main Results:

• The PET/CT scan confirmed reduced striatal uptake, consistent with Parkinson's disease.
• An unexpected focal accumulation of 18F-PR04.MZ was observed in the right frontal bone.
• CT imaging identified a stable, well-circumscribed, hypodense lesion consistent with fibrous dysplasia.

Conclusions:

• The novel radiotracer 18F-PR04.MZ effectively visualized reduced DAT binding in Parkinson's disease.
• DAT PET/CT imaging can potentially detect incidental bone pathologies like fibrous dysplasia.
• This case highlights the importance of careful interpretation of PET/CT scans for unexpected findings.